This content addresses several related principles in oncology therapeutics and risk stratification: (1) dual immune checkpoint blockade (combined CTLA-4 and PD-1 inhibition) as a first-line treatment paradigm distinct from single-agent checkpoint inhibition or cytotoxic chemotherapy, evaluated against chemotherapy backbones via randomized comparative trials; (2) the combination of a targeted tyrosine kinase inhibitor with an orthogonal-pathway inhibitor (e.g., an angiogenesis-pathway agent added to an oncogene-driver-pathway inhibitor) as a strategy to extend progression-free survival, with an accompanying toxicity trade-off; and (3) the use of incidentally acquired imaging data (radiotherapy planning scans) to derive a quantitative biomarker (coronary artery calcification score) for stratifying long-term cardiovascular risk in cancer survivors. These sit within oncologic therapeutics (immuno-oncology and combination-drug trial design) and cancer survivorship/late-effects epidemiology, respectively, both examples of using structured comparative-trial or biomarker-based evidence to change or refine standard of care.
This content addresses several related principles in oncology therapeutics and risk stratification: (1) dual immune checkpoint blockade (combined CTLA-4 and PD-1 inhibition) as a first-line treatment…